<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 7, 2000 (November 2, 2000)
BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)
Delaware 000-26727 68-0397820
(State or other jurisdiction of (Commission (IRS Employer
incorporation) File Number) Identification No.)
371 Bel Marin Keys Boulevard, 94949
Suite 210 (Zip Code)
Novato, California
(Address of principal
executive offices)
(415) 884-6700
(Registrant's telephone number,
including area code)
<PAGE>
Item 5. Other Events
Resignation of Dr. John C. Klock as director and consultant.
On November 2, 2000, Dr. John C. Klock submitted his resignation as a member of
the BioMarin Pharmaceutical Inc. (the "Company") Board of Directors and as a
consultant to the Company. Dr. Klock's resignation indicated that he is
resigning in order to devote substantially all of his working efforts to other
ventures, particularly early stage companies.
Dr. Klock resigned his post as president of the Company effective July 31 of
this year but continued to serve as a consultant to ensure a smooth transition
of his responsibilities to other members of the Company's executive team.
The Company's Board of Directors intends to initiate a search to identify an
appropriate replacement for Dr. Klock on the Board of Directors.
Item 7. Financial Statements and Exhibits
None.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
BioMarin Pharmaceutical Inc.
By: /s/ Fredric D. Price
---------------------------------------
Fredric D. Price
Chairman and
Chief Executive Officer
Date: November 7, 2000
